Influenza Diagnostics Market Size, Share, Growth Analysis, and Forecast

The Influenza Diagnostics Market is undergoing technological transformation as healthcare providers increasingly prioritize accurate, rapid, and accessible detection of influenza infections. Molecular diagnostics, point-of-care platforms, automated laboratory systems, and multiplex respiratory panels are reshaping testing workflows and creating new opportunities for diagnostic manufacturers.

Market Research Future estimates that the global influenza diagnostics market reached USD 1.94 billion in 2025. The market is expected to grow from USD 2.06 billion in 2026 to USD 3.53 billion by 2035, representing a CAGR of 6.15% during the forecast period.

Molecular platform migration is one of the strongest growth factors. Healthcare institutions are increasingly moving toward technologies such as RT-PCR and isothermal amplification because they can provide greater sensitivity and faster turnaround compared with traditional culture-based approaches. MRFR indicates that RT-PCR generated approximately USD 0.54 billion in revenue in 2025, demonstrating its important position in hospital laboratory workflows.

At the same time, emerging technologies are creating opportunities for disruption. CRISPR-based diagnostic assays are attracting attention because they can combine molecular-level detection with simpler testing workflows. According to MRFR, CRISPR-based assays are projected to grow at a 10.0% CAGR through 2035, making them one of the fastest-growing test-type categories.

Automation is another important development. AI-enabled laboratory workflow systems can assist with sample processing, quality control, and result interpretation. These technologies can increase laboratory throughput while reducing manual workload. As healthcare organizations face workforce shortages, automated diagnostic systems may become increasingly valuable.

Multiplex respiratory panels represent another major opportunity. Rather than testing only for influenza, combination platforms can simultaneously identify influenza, COVID-19, RSV, and other respiratory pathogens. This approach can improve diagnostic efficiency and help clinicians distinguish between infections with overlapping symptoms.

Point-of-care diagnostics are also gaining importance. MRFR projects point-of-care settings to expand at a 9.85% CAGR through 2035. Retail pharmacies, urgent-care centers, and home-based testing environments are therefore expected to become increasingly important channels for influenza diagnostics.

As technology continues to improve, the market is expected to move toward faster, multiplexed, automated, and decentralized testing. Companies investing in molecular platforms, CRISPR technologies, AI-enabled workflows, and integrated respiratory panels are likely to benefit from this evolution.